Clinical implications of pharmacogenomics of statin treatment

Pharmacogenomics J. 2006 Nov-Dec;6(6):360-74. doi: 10.1038/sj.tpj.6500384. Epub 2006 Mar 21.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Cytochrome P-450 CYP3A / genetics
  • Cytochrome P-450 Enzyme System / genetics
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / genetics
  • Membrane Transport Proteins / genetics
  • Membrane Transport Proteins / metabolism
  • Organic Anion Transporters / genetics
  • Organic Anion Transporters / metabolism
  • Pharmacogenetics*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Membrane Transport Proteins
  • Organic Anion Transporters
  • cytochrome P-450 CYP2C subfamily
  • Cytochrome P-450 Enzyme System
  • Cytochrome P-450 CYP3A